Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cellular and gene therapy for major histocompatibility complex class II deficiency.

Franck Matheux1, Jean Villard

  • 1Immunology and Transplant Unit, Division of Immunology and Allergology, Geneva University Hospital, 1211 Geneva 4, Switzerland.

News in Physiological Sciences : an International Journal of Physiology Produced Jointly by the International Union of Physiological Sciences and the American Physiological Society
|May 15, 2004
PubMed
Summary

Major histocompatibility complex (MHC) class II deficiency, a primary immunodeficiency, is being treated in mice using lentiviral vectors. A new diagnostic test was also optimized to identify defective MHC II genes in patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

HLA-B*15:01 and HLA-DRB1*07:01 as novel markers of acute GVHD in pediatric HSCT.

Bone marrow transplantation·2026
Same author

Influence of the shared epitope on the effectiveness of biologic antirheumatic agents in European patients with rheumatoid arthritis.

RMD open·2026
Same author

Gelatin Sponge-Embedded Adipose-Derived Stromal Cells Enable Allogeneic Application for Revascularization of Ischemic Wounds.

International journal of molecular sciences·2026
Same author

Normalization of nCounter Gene Expression Data Alters Molecular Diagnostics in Kidney Transplantation.

Journal of the American Society of Nephrology : JASN·2026
Same author

Preformed donor-specific antibodies are associated with acute rejection and biliary complications after liver transplantation: A Swiss Transplant Cohort Study analysis.

Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society·2026
Same author

IL1B rs1143627 and IL17A rs8193036 in the risk of Acute Graft Versus Host Disease in pediatric HSCT.

Leukemia research·2026

Area of Science:

  • Immunology
  • Genetics
  • Gene Therapy

Background:

  • Major histocompatibility complex (MHC) class II deficiency is a severe primary immunodeficiency.
  • This condition impairs the adaptive immune system's ability to recognize and respond to pathogens.

Purpose of the Study:

  • To evaluate the efficacy of lentiviral vectors for gene therapy in a mouse model of MHC class II deficiency.
  • To develop and optimize a direct genetic correction diagnostic test for identifying specific gene defects in MHC II-deficient patients.

Main Methods:

  • Utilized lentiviral vectors for gene delivery in a preclinical mouse model.
  • Developed a genetic correction approach to create a diagnostic assay.
  • Applied the diagnostic test to identify defective MHC II genes in patients.

Related Experiment Videos

Main Results:

  • Successful application of lentiviral vectors demonstrated potential for gene therapy in MHC class II deficiency.
  • Optimized a diagnostic test enabling precise identification of the causative genetic defect in patients.
  • The diagnostic test can distinguish between defects in the four distinct MHC II genes.

Conclusions:

  • Lentiviral vector gene therapy shows promise for treating MHC class II deficiency.
  • The optimized diagnostic test is crucial for accurate patient diagnosis and personalized treatment strategies.
  • Advancements in gene therapy and diagnostics offer new hope for individuals with primary immunodeficiencies.